Impel Pharmaceuticals
Manufacturing · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Elliott Ave W Ste 260, Seattle, Wash...Phone Number
(206) 568-1466Website
www.impelpharma.comRevenue
$21 MillionStock Symbol
IMPLIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Impel Pharmaceuticals
Impel Pharmaceuticals Inc. is a Seattle based commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for central nervous system disorders.Explore more
Impel Pharmaceuticals Org Chart
MM
Vice President, Quality
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Impel Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Impel Pharmaceuticals is spiking on competitors!
Impel Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Impel Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Impel Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Impel Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Impel Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Impel Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Impel Pharmaceuticals
Recommended Actions
Find VP level buyers at Impel Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Impel Pharmaceuticals
Compare insights from companies similar to Impel Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Impel Pharmaceuticals
$21M
51-200
Public
$346.6M
2008
EG
Ellen GettenbergSenior VP, Commercial Operations
$192.8M
201-500
Private
$488.9M
2006
JD
Jayne DonnellyVice President, Executive Operations and Administration
Company Profile Activity
Activity Insights
Impel Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Impel Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Impel Pharmaceuticals.
Impel Pharmaceuticals financials insights
Gather financial insights about Impel Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series B
$12M
2016
Debt
$1.1M
Series C
$36M
2018
Series D
$67.5M
2021
Stock Offering
$80M
Debt
$50M
2022
Other Financing Round
$100M
Impel Pharmaceuticals Tech Stack
A closer look at the technologies used by Impel Pharmaceuticals
See more technologies
Most Recent Scoops
Pain Point
Bankruptcy
Left Company
Executive Move
Left Company
Executive Move
Lateral Move
Executive Move
Board of Directors
Funding
Impel Pharmaceuticals News & Media
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company...Impel Pharmaceuticals Inc. Announces Resignation of Michael Kalb as Chief Financial ...
On December 1, 2023, Michael Kalb announced resignation from his position as Chief Financial Officer of Impel Pharmaceuticals Inc. with his last day to be December 31, 2023....Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation
Impel Celebrates Its One-Year Anniversary as a Public Company Today at the Nasdaq Stock Market Closing Bell Ceremony Starting at 3:45 p.m. EDT Impel Celebrates Its One-Year Anniversary as a Public Company Today at the Nasdaq Stock Market Closing Bell Ceremony Starting at 3:45 p.m. EDTImpel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25
Impel Celebrates Its One-Year Anniversary as a Public Company Impel Celebrates Its One-Year Anniversary as a Public Company
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Impel Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Impel Pharmaceuticals Inc. is a Seattle based commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for central nervous system disorders.... Read More
